Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach
Abstract Chronic tinnitus is a common neurological disorder that affects millions of patients globally with no available successful pharmacotherapy. It can be extremely bothersome to some patients to the extent that it occasionally qualifies as a disability that can hinder them from leading a normal life. In this short communication, the author discusses how he suffered from idiopathic tinnitus and how he managed to adopt a combined pathophysiological and pharmacological approach to the reason for the first time in the medical literature that low-dose metformin might be safely and effectively repurposed to manage at least a subset of tinnitus patients while discussing the potential role of adenosine receptor agonists as potential future tinnitus therapeutics..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 32(2024), 2 vom: 31. Jan., Seite 945-948 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kelleni, Mina T. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Adenosine |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s10787-023-01421-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055479065 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055479065 | ||
| 003 | DE-627 | ||
| 005 | 20240411064651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-023-01421-8 |2 doi | |
| 035 | |a (DE-627)SPR055479065 | ||
| 035 | |a (SPR)s10787-023-01421-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Kelleni, Mina T. |e verfasserin |0 (orcid)0000-0001-6290-6025 |4 aut | |
| 245 | 1 | 0 | |a Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Abstract Chronic tinnitus is a common neurological disorder that affects millions of patients globally with no available successful pharmacotherapy. It can be extremely bothersome to some patients to the extent that it occasionally qualifies as a disability that can hinder them from leading a normal life. In this short communication, the author discusses how he suffered from idiopathic tinnitus and how he managed to adopt a combined pathophysiological and pharmacological approach to the reason for the first time in the medical literature that low-dose metformin might be safely and effectively repurposed to manage at least a subset of tinnitus patients while discussing the potential role of adenosine receptor agonists as potential future tinnitus therapeutics. | ||
| 650 | 4 | |a Tinnitus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Long COVID |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metformin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Caffeine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adenosine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adenosine receptors |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Springer International Publishing, 1991 |g 32(2024), 2 vom: 31. Jan., Seite 945-948 |w (DE-627)SPR013448595 |w (DE-600)2047989-X |x 1568-5608 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:2 |g day:31 |g month:01 |g pages:945-948 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10787-023-01421-8 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.38 |q VZ |
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 2 |b 31 |c 01 |h 945-948 | ||